top of page


FDA approves Roche's Gazyva as first specifically authorised treatment for primary membranous nephropathy
The FDA has approved Roche's Gazyva for primary membranous nephropathy, establishing the first specifically authorised treatment for the condition after Phase III evidence demonstrated substantially higher complete proteinuria remission rates than tacrolimus.

nuaxia
1 hour ago2 min read


Celltrion licenses Kaigene anti-APRIL antibody KG013 for up to $580.5 million
Celltrion has licensed Kaigene's next-generation anti-APRIL antibody KG013 in a global agreement worth up to $580.5 million plus royalties.

nuaxia
Oct 232 min read


FDA grants accelerated approval to AstraZeneca Ultomiris for primary IgA nephropathy in adults
The FDA has granted accelerated approval to AstraZeneca's Ultomiris for adults with primary IgA nephropathy, introducing a C5 complement inhibitor treatment to reduce proteinuria.

nuaxia
Oct 222 min read


CSL and Alentis sign lixudebart partnership worth up to $1.555bn plus profit share
CSL and Alentis Therapeutics have entered a global lixudebart partnership worth up to $1.555 billion, with future profits shared between the companies.

nuaxia
Oct 62 min read


BioPorto advances US regulatory pathway for adult AKI test following FDA feedback
The company has expanded its US clinical validation study to support a future FDA submission for its adult NGAL kidney injury test while continuing to grow adoption of the biomarker in clinical practice.

nuaxia
Aug 212 min read


Lilly and Ascidian Enter $1.9bn Partnership to Advance RNA Exon Editing in Monogenic Kidney Disease
Eli Lilly and Ascidian Therapeutics have entered into a multi-year strategic collaboration worth up to $1.9bn, focused on developing RNA exon-editing therapies for undisclosed monogenic kidney diseases.

nuaxia
Jun 43 min read
bottom of page